ClinicalTrials.gg
CompletedNCT03251261CMVUpdated Jan 14, 2019

Detection of Cytomegalovirus Virus in Neonates

An observational study in CMV, sponsored by Meridian Bioscience, Inc.. Completed at 5 sites in 4 countries. Open to participants aged Up to 20 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-14.

Sponsored by Meridian Bioscience, Inc. (part of SD Biosensor) · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,615
Ages
Up to 20 Days
Sex
All
01

Study summary

To evaluate the illumigene CMV assay, using the illumipro-10 with neonates (up to 21 days of age) saliva swabs

02

Conditions studied

  • CMV
03

In context

Lead sponsor

Meridian Bioscience, Inc. is the lead sponsor of 27 studies on the registry; none are open to participants now.

First submitted before Meridian Bioscience, Inc. became part of SD Biosensor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 20 Days
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Saliva swab specimens from all neonates up to 21 days of age may be collected and tested

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Saliva swab specimens from neonates up to 21 days of age
  • Saliva swab sample placed in a nonnutritive transport medium or in a plastic sterile tube without medium.
  • Flocked-nylon swabs

Exclusion criteria

Exclusion Criteria:

  • Samples other than saliva swab from patients up to 21 days of age.
  • Swabs other than flocked-nylon.
  • Swabs in a viral transport media not defined in the Use Only package insert
  • Multiple specimens from the same patient.
  • Specimens received in the laboratory in unsatisfactory containers or condition.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,615 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Specimen collection

    Device: illumigene CMV assay, illumipro-10

Interventions

  • Deviceillumigene CMV assay, illumipro-10

    CMV assay for detection of CMV

06

What researchers measure

Primary outcomes

  1. Qualitative detection of CMV to aid in the diagnosis of CMV

    Test each sample for CMV detection

    Time frame: within 30 days of sample collection

07

Study locations

5 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • University of Utah
    Salt Lake City, Utah 84112, United States
  • The Prince of Wales Hospital
    Randwick, New South Wales 2031, Australia
  • British Columbia Children's Hospital / British Columbia Women's Hospital
    Vancouver, British Coloumbia V6H 3N1, Canada
  • Ospedale Sant'Orsola
    Via Massarenti 19, Province Of Bologna 40138, Italy
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2017 to primary completion in Mar 2018, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2017
First posted
Aug 16, 2017
StartActual
Aug 2, 2017
Primary completionActual
Mar 5, 2018
CompletionActual
Mar 5, 2018
Last update
Jan 14, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03251261
Responsible party
Sponsor
First posted
Aug 16, 2017
Start date
Aug 2, 2017
Primary completion
Mar 5, 2018
Completion
Mar 5, 2018
Last update
Jan 14, 2019

Study contacts

Julie M Kesler
study director · Meridian Bioscience
Ken Kozak
study chair · Meridian Bioscience

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion